BT Slingsby, Renalys Pharma CEO
July 17, 2024 01:00 AM EDT
Financing
R&D

Re­nalys rais­es $37.8M to take Travere's kid­ney dis­ease drug in­to Phase 3 tri­al in Japan

Katherine Lewin

News Reporter

Japan­ese biotech Re­nalys Phar­ma has raised $37.8 mil­lion (¥6 bil­lion) in a Se­ries A round to work on an ap­proval in Japan for the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times